Playlist

Turkmenistan Approves National Program for Mother and Child Healthcare for 2026–2030

21 Jun. 07:36

Source

To improve the quality of healthcare for mothers and children, ensure their physical and psychological well-being, optimize overall public health indices, and increase life expectancy during the Revival of the New Era of the Powerful State, the President of Turkmenistan signed a dedicated Decree. The strategic document was officially announced by the "Watan" news program.

In accordance with the Decree, the National Program for Mother and Child Healthcare in Turkmenistan for 2026–2030, titled "Healthy Mother – Healthy Child – Healthy Future," along with its comprehensive Action Plan for implementation, has been formally approved. The framework is designed to restructure the operational efficiency of the state's clinical, pediatric, and reproductive healthcare systems.

The program focuses on enhancing preventive medicine, upgrading diagnostic technologies at local health centers, and expanding early childhood development indicators across all provinces. Line ministries have been instructed to ensure the timely execution of the objectives to strengthen corporate healthcare delivery.

Public health analysts emphasize that this five-year national strategy closely aligns with the global standards set by the World Health Organization (WHO) and UNICEF. By deploying targeted resources, Turkmenistan reinforces its long-term sustainable development commitments toward family welfare and child health infrastructure.

‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌

Simple Vitamin Shows Surprising Results in Pre-Cancerous Blood Conditions, Study Finds

Today in 02:02

Source

Daily high-dose supplementation of vitamin C can significantly reduce mortality risks and help prevent severe medical complications in patients with pre-cancerous blood conditions. Researchers from the Van Andel Institute in the United States and Copenhagen University Hospital in Denmark reached this conclusion following a comprehensive three-year follow-up study. The international "EVITA" trial involved volunteers who were administered 1,000 mg of vitamin C daily over the course of a year, while a control group received a placebo.

Although initial hypotheses suggested vitamin C might directly inhibit abnormal cell proliferation, researchers found its primary benefit lay in strengthening the body, reducing systemic inflammation, and lowering rates of anemia, pneumonia, and internal bleeding. Over the three-year observation period, the vitamin C group exhibited a significantly higher survival rate compared to the placebo group. While experts emphasize that these findings remain preliminary and require larger clinical trials before reshaping formal medical treatment protocols, vitamin C continues to show promising potential in supportive patient care.

‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌